Exemestane-d3

• Description :

  Exemestane-d3 is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research[1][2].

• Product Name Alternative :

  FCE 24304-d3; EXE-d3

• UNSPSC :

  12352211

• Target :

  Cytochrome P450; Isotope-Labeled Compounds

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Metabolic Enzyme/Protease; Others

• Field of Research :

  Cancer; Endocrinology

• Solubility :

  10 mM in DMSO

• Smiles :

  C[C@]1([C@](CC2)([H])[C@]3([H])CC(C4=CC(C=C[C@]4(C([2H])([2H])[2H])[C@@]3([H])CC1)=O)=C)C2=O

• Molecular Formula :

  C20H21D3O2

• Molecular Weight :

  299.42

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Di Salle, E., et al., Novel aromatase and 5 alpha-reductase inhibitors. J Steroid Biochem Mol Biol, 1994. 49 (4-6) : p. 289-94.|[3]Miki, Y, et al. Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. Bone. 2004 Sep 1;10 (17) :5717-23.|[4]Goss, P.E., et al., Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res, 2004. 10 (17) : p. 5717-23.|[5]Zaccheo, T., D. Giudici, and E. Di Salle, Inhibitory effect of combined treatment with the aromatase inhibitor exemestane and tamoxifen on DMBA-induced mammary tumors in rats. J Steroid Biochem Mol Biol, 1993. 44 (4-6) : p. 677-80.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• Isoform :

  Aromatase/CYP19A1